International respiratory societies call for collaboration on asthma
The Forum of International Respiratory Societies (FIRS) is calling for improved collaboration and funding to prevent and treat asthma.
In World Asthma Day on May 3, FIRS says stakeholders must collaborate locally and globally to ensure adequate funding and resources are available to implement effective preventative and therapeutic strategies.
FIRS brings together the world’s leading international respiratory societies to work together to improve lung health globally. Members include the European Respiratory Society (ERS), International Union Against Tuberculosis and Lung Disease (The Union), the American Thoracic Society (ATS), and the American College of Chest Physicians (CHEST). The goal of the Forum is to unify and enhance efforts to improve lung health through the combined work of its 70,000+ members globally.
According to the Global Asthma Report 2014, up to 334 million people worldwide have asthma. Approximately 4.5% of young adults have been diagnosed with asthma and/or are taking asthma medication. An estimated 14% of children have had asthma symptoms in the past year.
In a statement issued by the ATS, FIRS says leaders in respiratory health must unite globally to invest in community-led solutions to improve quality of life, and reduce morbidity and mortality in asthma. It is calling on countries and organisations to invest and take necessary actions to encourage people-centred prevention, treatment and care to ensure that every person with asthma has access to high-value care.
World Asthma Day is an annual event organised by the Global Initiative for Asthma (GINA) to improve asthma awareness and care around the world. The theme for this year’s event is ‘You can control your asthma’ and it will be held on May 3.
The following new article has just been published in Asthma Research and Practice
Watkins K, Fisher C, Misaghian J, Schneider C, Clifford R
Asthma Research and Practice 2016, 2 :8 (4 May 2016)
Featured: Sickle cell disease: wheeze or asthma?
This review on the association between sickle cell disease (SCD) and asthma focusses on: 1) Our current understanding of the epidemiology of asthma, wheezing, airway obstruction, and airway responsiveness among patients with SCD; 2) The evidence supporting associations with SCD morbidity; 3) Our understanding of the pathophysiology of airway inflammation in SCD; 4) Current approaches to diagnosis and management of asthma in SCD; and 5) Future directions.
Child maltreatment and pediatric asthma: a review of the literature
Child maltreatment is a common problem with known adverse consequences, yet its contributions to the development and course of pediatric asthma are only poorly understood.
This review first describes possible pathways connecting child maltreatment to pediatric asthma, including aspects of the physical home environment, health behaviors and disease management, and psychological consequences of child maltreatment. We subsequently review existing studies, which generally report an association between maltreatment experiences and asthma outcomes in childhood. However, this literature is in its early stages; there are only a handful studies, most of them rely on self-reports of both child maltreatment and asthma history, and none have investigated the physiological underpinnings of this association. Taken together, however, the studies are suggestive of child maltreatment playing a role in pediatric asthma incidence and expression that should be explored further.
Existing data are sparse and do not allow for specific conclusions. However, the data are suggestive of child maltreatment influencing asthma risk and morbidity long before the adult years. Future research should focus on understanding how child maltreatment contributes to asthma disease risk and progression in this highly vulnerable population.
CXC chemokine superfamily induced by Interferon-γ in asthma: a cross-sectional observational study
The following new article has just been published in Asthma Research and Practice
Takaku Y, Soma T, Uchida Y, Kobayashi T, Nakagome K, Nagata M
Asthma Research and Practice 2016, 2 :6 (17 March 2016)
Treatment of asthma in young children: evidence-based recommendations
In the present review, we focus on evidence-based data for the use of inhaled corticosteroids (ICS), leukotriene receptor antagonist (LTRA), long-acting beta2-agonits (LABA) and oral corticosteroids (OCS), with a special emphasis on well-performed randomized clinical trials (RCTs) and meta-analyses of such trials for the chronic management of asthma/wheeze in infants and preschoolers. Results: Seven meta-analyses and 14 RCTs were reviewed. Daily ICS should be the preferred drug for infants/preschoolers with recurrent wheezing, especially in asthmatics. For those with moderate or severe episodes of EVW, the use of high intermittent ICS doses significantly reduce the use of OCS. There is no evidence of effect of intermittent ICS at low-moderate dose in preschoolers with mild EVW episodes. In preschoolers with asthma, there were no significant differences between daily vs. intermittent ICS in terms of asthma exacerbations with insufficient power to conclude to equivalence; however, for other asthma control outcomes, daily ICS works significantly better than intermittent ICS for older children. Daily ICS is superior to daily or intermittent LRTA for reducing symptoms, preventing exacerbations, and improving lung function. No RCTs testing combination therapy with ICS and LABA (or LTRA) were published in infant/preschoolers. Parent-initiation of OCS at the first sign of symptoms is not effective in children with recurrent wheezing episode. In terms of ICS safety, growth suppression is dose and molecule-dependent but it’s effect is not cumulative beyond the first year of therapy and may be associated with some catch-up growth while on or off therapy. Linear growth must be monitored as individual susceptibility to ICS drugs may vary considerably.
Join WAO at Interasma for the COSA Symposium
Join WAO at Interasma for the COSA Symposium: Approaches to Severe Asthma. WAO experts will present on severe asthma during Interasma’s World Congress on Asthma (WCA) in Madrid, Spain, on 14 March 2016 from 16:30 to 18:00.
Prof Lanny Rosenwasser will speak on “Cytokine Families and Receptors as Treatment Targets in Severe Asthma”. Prof Ignacio Ansotegui will speak on “Small Airways in Asthma”, and Prof Mario Sánchez-Borges will speak on “Acute Asthma Induced by Mite-Contaminated Foods.”
INTERASMA'S WORLD CONGRESS ON ASTHMA 2016 - MADRID, SPAIN
World Allergy Organization COSA Symposium: Approaches to Severe Asthma
Monday, 14 March 2016
16:30 to 18:00
G Walter Canonica, University of Genoa
Sergio Bonini, Second University of Naples
Cytokine Families and Receptors as Treatment Targets in Severe Asthma
Lanny Rosenwasser, Children’s Mercy Hospital
Small Airways in Asthma
Ignacio Ansotegui, Hospital Quirón Bizkaia
Acute Asthma Induced by Mite-Contamined Foods
Mario Sanchez-Borges, Centro Médico Docente – La Trinidad
GINA will be present in the WCA 2016
World Congress of Asthma 2016. Madrid, March 12-15. General Information.
Calle del Capitán Haya, 43
Climate and Dress Code
Madrid and its metropolitan area has a Mediterranean climate with continental influences, with mild cool winters and hot summers. The average temperature in March it varies from +8oC (46oF) to +20oC (60oF). The Spanish capital is in the center of the Iberian Peninsula, 622 meters above sea level. The dress code will be informal throughout the Congress.
The local currency is the Euro (EUR).
The WCA 2016 Congress in Madrid will include an exhibition that will be open from 12-15 March.
The official language of the Congress is English.
The time zone in Madrid is Central European Time (CEST / GMT +1) .
Participants are advised to make their own arrangements with respect to entering Spain.
Please apply for a visa within a reasonable time prior to making your bookings.
Travel and Health Insurance
It is strongly recommended that all participants purchase adequate coverage for health, travel and private liability insurance before departing from their home countries. The Organizers will not accept responsibility for personal injury, loss or damage to private, personal property of participants, accompanying persons and exhibitors.